FC
UTHR icon

Fairscale Capital’s United Therapeutics UTHR Stock Holding History

Fairscale Capital’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.1K Hold
50
– – 0.02% 258
2026
Q1 		$29.6K Hold
50
– – 0.02% 240
2025
Q4 		$24.4K Hold
50
– – 0.02% 251
2025
Q3 		$21K Hold
50
– – 0.01% 273
2025
Q2 		$13.7K Hold
50
– – 0.01% 304
2025
Q1 		$15.4K Hold
50
– – 0.01% 235
2024
Q4 		$17.6K Hold
50
– – 0.02% 230
2024
Q3 		$17.9K Hold
50
– – 0.02% 229
2024
Q2 		$16.4K Buy
+50
New +$13.2K 0.01% 237

Other funds holding UTHR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
Norges Bank
Norges Bank Oslo, Norway $1T AUM

Fairscale Capital's UTHR Position: Q2 2026 in Review

Fairscale Capital held its United Therapeutics (UTHR) position steady in Q2 2026 at 50 shares worth $27.1K. The position accounts for 0.02% of the portfolio, ranked #258.

Fairscale Capital first reported a position in UTHR in Q2 2024 and has held it in 9 quarters since. The position peaked at $29.6K in Q1 2026. 880 funds tracked by Wall St. Rank hold UTHR as of Q2 2026.

  • Fairscale Capital held 50 shares of United Therapeutics worth $27.1K as of Q2 2026.
  • Fairscale Capital left its United Therapeutics share count unchanged in Q2 2026.
  • United Therapeutics made up 0.02% of Fairscale Capital's portfolio in Q2 2026, its #258 holding.
  • Fairscale Capital first reported a position in United Therapeutics in Q2 2024 and has held it in 9 quarters since.
  • Fairscale Capital's United Therapeutics position peaked at $29.6K in Q1 2026.
  • 880 funds tracked by Wall St. Rank held United Therapeutics as of Q2 2026.

Based on Fairscale Capital's 13F filing for Q2 2026, filed 7 Aug 2026.